Organization Profile

You just read:

National Agreement Reached between Pan-Canadian Pharmaceutical Alliance and Bristol-Myers Squibb for Immuno-Oncology Treatment OPDIVO® (nivolumab)

News provided by

Bristol-Myers Squibb Canada

Feb 10, 2017, 08:00 ET